ERS Genomics signs CRISPR deal with Lonza

14-12-2018

ERS Genomics signs CRISPR deal with Lonza

ralwel / iStockphoto.com

ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.                       


CRISPR/cas9, Eric Rhodes, Syngulon, patent dispute, University of California, University of Vienna, Emmanuelle Charpentier

LSIPR